IGC Pharma Expands AI Platform with Advanced Diagnostic Model for Alzheimer’s and Dementia Detection March 4, 2025 Read More »
IGC Pharma Expands Holiby™ Product Line with –Longevity’ and –Renew’ – Targeting the Multi-Billion-Dollar Anti-Aging Market February 20, 2025 Read More »
IGC Pharma Expands into $75 Billion Wellness Market with the Launch of Holiby™ February 11, 2025 Read More »
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer’s Disease January 28, 2025 Read More »
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor January 21, 2025 Read More »
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets January 13, 2025 Read More »
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer’s Agitation CALMA and Expands Recruitment Strategy January 8, 2025 Read More »
IGC Pharma Announces Participation in BioPartnering @ JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 December 19, 2024 Read More »
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer’s Therapy Addressing Cognitive Impairment and Underlying Disease Pathology December 2, 2024 Read More »
